Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARCA Biopharma Inc ABIO

Healthcare Biotechnology
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is... see more

Recent & Breaking News (NDAQ:ABIO)

ARCA biopharma Provides GENETIC-AF Clinical Trial Update

Business Wire March 16, 2015

ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-isomer Formulation of Gencaro

Business Wire February 4, 2015

Arca biopharma Announces Activation of First Canadian Genetic-AF Clinical Trial Site

Business Wire December 11, 2014

ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola

Business Wire December 10, 2014

ARCA biopharma Announces Management Transitions

Business Wire December 1, 2014

LabCorp/ARCA biopharma GENETIC-AF Poster Presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America

Business Wire September 16, 2014

LabCorp/ARCA biopharma GENETIC-AF Poster Selected for Presentation at the 18th Annual Scientific Meeting of the Heart Failure Society of America

Business Wire September 8, 2014

ARCA biopharma Announces Health Canada Acceptance of Genetic-AF Clinical Trial Application

Business Wire August 18, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

Robert E. Conway Elected Chairman of ARCA biopharma Board of Directors

Business Wire June 9, 2014

ARCA biopharma to Present at the Growth Capital Expo 2014

Business Wire April 22, 2014

ARCA biopharma Announces Screening of First Patient in Phase 2B/3 Clinical Trial Evaluating Gencaro in Atrial Fibrillation

Business Wire April 17, 2014

ARCA biopharma Files Shelf Registration Statement

Business Wire April 4, 2014

ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear Channel Business Talk Radio

Marketwired March 19, 2014

Dan Mitchell Joins ARCA biopharma Board of Directors

Business Wire February 12, 2014

ARCA biopharma Announces Pricing of $9 Million Public Offering of Common Stock and Warrants

Business Wire February 4, 2014

ARCA biopharma Announces Proposed Public Offering of Common Stock and Warrants

Business Wire February 3, 2014

ARCA biopharma Announces US FDA Acceptance of Gencaro Companion Diagnostic Test IDE

Business Wire January 8, 2014

ARCA biopharma to Present at Biotech Showcase 2014

Business Wire January 7, 2014

ARCA biopharma Announces IDE Submission to US FDA for Gencaro Companion Diagnostic Test

Business Wire December 5, 2013